Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
Protective neutralizing epitopes in SARS‐CoV‐2
H Liu, IA Wilson - Immunological reviews, 2022 - Wiley Online Library
The COVID‐19 pandemic has caused an unprecedented health crisis and economic burden
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …
worldwide. Its etiological agent SARS‐CoV‐2, a new virus in the coronavirus family, has …
[HTML][HTML] Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
The BQ and XBB subvariants of SARS-CoV-2 Omicron are now rapidly expanding, possibly
due to altered antibody evasion properties deriving from their additional spike mutations …
due to altered antibody evasion properties deriving from their additional spike mutations …
Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike
A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant, BA.
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
2.86, has emerged and spread to numerous countries worldwide, raising alarm because its …
Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5
Abstract SARS-CoV-2 Omicron subvariants BA. 2.12. 1 and BA. 4/5 have surged notably to
become dominant in the United States and South Africa, respectively,. These new …
become dominant in the United States and South Africa, respectively,. These new …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2
KYA Huang, X Chen, A Mohapatra, HTV Nguyen… - Nature …, 2023 - nature.com
Antibody-mediated immunity plays a crucial role in protection against SARS-CoV-2 infection.
We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited …
We isolated a panel of neutralizing anti-receptor-binding domain (RBD) antibodies elicited …
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into …
variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into …
[HTML][HTML] Broadly neutralizing antibodies against COVID-19
The COVID-19 pandemic caused by SARS-CoV-2 has led to hundreds of millions of
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
infections and millions of deaths, however, human monoclonal antibodies (mAbs) can be an …
[HTML][HTML] Evolving antibody evasion and receptor affinity of the Omicron BA. 2.75 sublineage of SARS-CoV-2
Summary SARS-CoV-2 Omicron BA. 2.75 has diversified into multiple subvariants with
additional spike mutations and several are expanding in prevalence, particularly CH. 1.1 …
additional spike mutations and several are expanding in prevalence, particularly CH. 1.1 …